All News

Among patients with prostate cancer, a high omega-3, low-omega-6 diet with fish oil led to a Ki-67 index decrease.

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in metastatic urothelial carcinoma.

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

I found community after my metastatic breast cancer diagnosis, but recent discord in cancer support groups makes me fear we're losing these vital connections.

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death by 46%, per ARANOTE data.

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting.

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's sarcoma diagnosis.

Breyanzi has shown significant efficacy and durable responses in patients with marginal zone lymphoma.

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower death risk with Talzenna plus Xtandi.

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been discontinued.

The prognosis of patients with gastrointestinal stromal tumors is significantly impacted by gastrointestinal bleeding.

I have been frustrated lately by my increasing slowness following an blood cancer diagnosis, which has become noticeable to others.

Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.

The FDA has approved Adcetris plus Revlimid and Rituxan in adults with relapsed or refractory large B-cell lymphoma.

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

Dr. Suneel Kamath discusses the ALASCCA study in colorectal cancer and highlighted the importance of next-generation sequencing and testing.

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.

Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.

The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine dehydrogenase deficiency.

As a cancer survivor, I face added stress with an upcoming black belt test and "scanxiety" before my annual CT scan and oncology appointment.

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.